314 related articles for article (PubMed ID: 30199148)
41. Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations.
Yang B; Lee H; Um SW; Kim K; Zo JI; Shim YM; Jung Kwon O; Lee KS; Ahn MJ; Kim H
Lung Cancer; 2019 Mar; 129():28-34. PubMed ID: 30797488
[TBL] [Abstract][Full Text] [Related]
42. Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer.
Vincenten J; Smit EF; Vos W; Grünberg K; Postmus PE; Heideman DA; Snijders PJ; Meijer G; Kuik J; Witte BI; Thunnissen E
J Thorac Oncol; 2012 Oct; 7(10):1522-7. PubMed ID: 22982653
[TBL] [Abstract][Full Text] [Related]
43. [Thyroid transcription factor-1 level is associated with epidermal growth factor receptor mutation status in patients with advanced lung adenocarcinoma].
Niu Y; Wang H; Zhang G; Ma J; Wei B; Ma Z
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):919-23. PubMed ID: 25609130
[TBL] [Abstract][Full Text] [Related]
44. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
[TBL] [Abstract][Full Text] [Related]
45. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
46. ALK Mutation Status in EGFR-negative Non-small-cell Lung Cancer Patients in Bulgaria.
Djambazov SN; Vekov TY; Mekov EV; Slavchev GS; Petkov RE; Kostadinov DT; Konteva LT
Folia Med (Plovdiv); 2018 Sep; 60(3):397-401. PubMed ID: 30355843
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathologic characteristics and EGFR mutations in lung cancer patients aged below 45 years.
Xia J; Li H; Ji Y; Mi C; Chen G; Li P; Zhang R; Chen W; Wang J
Curr Probl Cancer; 2019 Aug; 43(4):363-370. PubMed ID: 30522775
[TBL] [Abstract][Full Text] [Related]
48. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
49. Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations.
Kriegsmann M; Harms A; Kazdal D; Fischer S; Stenzinger A; Leichsenring J; Penzel R; Longuespée R; Kriegsmann K; Muley T; Safi S; Warth A
Pathol Res Pract; 2018 Mar; 214(3):408-416. PubMed ID: 29487011
[TBL] [Abstract][Full Text] [Related]
50. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
51. Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.
Schilsky JB; Ni A; Ahn L; Datta S; Travis WD; Kris MG; Chaft JE; Rekhtman N; Hellmann MD
Lung Cancer; 2017 Jun; 108():205-211. PubMed ID: 28625636
[TBL] [Abstract][Full Text] [Related]
52. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
[TBL] [Abstract][Full Text] [Related]
53. Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy.
Sánchez-Font A; Chalela R; Martín-Ontiyuelo C; Albero-González R; Dalmases A; Longarón R; Alonso-Espinaco V; Curull V; Bellosillo B; Pijuan L
Cancer Cytopathol; 2018 Oct; 126(10):860-871. PubMed ID: 30291816
[TBL] [Abstract][Full Text] [Related]
54. Non-Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non-Small-cell Lung Cancer Favor Adenocarcinoma.
Shiran I; Heller E; Jessel S; Kamer I; Daniel-Meshulam I; Navon R; Urban D; Onn A; Bar J
Clin Lung Cancer; 2017 May; 18(3):316-323.e1. PubMed ID: 28237243
[TBL] [Abstract][Full Text] [Related]
55. Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.
Leichsenring J; Volckmar AL; Magios N; Morais de Oliveira CM; Penzel R; Brandt R; Kirchner M; Bozorgmehr F; Thomas M; Schirmacher P; Warth A; Endris V; Stenzinger A
Genes Chromosomes Cancer; 2017 Mar; 56(3):214-220. PubMed ID: 27750395
[TBL] [Abstract][Full Text] [Related]
56. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.
Sigel CS; Moreira AL; Travis WD; Zakowski MF; Thornton RH; Riely GJ; Rekhtman N
J Thorac Oncol; 2011 Nov; 6(11):1849-56. PubMed ID: 21841504
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients.
Haghgoo SM; Khosravi A; Mortaz E; Pourabdollah-Toutkaboni M; Seifi S; Sabour S; Allameh A
Clin Biochem; 2017 Apr; 50(6):293-300. PubMed ID: 27923629
[TBL] [Abstract][Full Text] [Related]
58. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
[TBL] [Abstract][Full Text] [Related]
59. [Driven Gene in Patients with Lung Squamous Cell Carcinoma:
Analysis of Clinicopathologic Characteristics and Prognosis].
Zhang T; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
[TBL] [Abstract][Full Text] [Related]
60. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
